Document is current
Any future updates will be listed below
-
Authors
Leibowitz, Mitchell L. https://orcid.org/0000-0003-1874-5441
Papathanasiou, Stamatis
Doerfler, Phillip A. https://orcid.org/0000-0001-7566-9073
Blaine, Logan J. https://orcid.org/0000-0003-0937-9216
Sun, Lili
Yao, Yu
Zhang, Cheng-Zhong https://orcid.org/0000-0001-8825-7158
Weiss, Mitchell J. https://orcid.org/0000-0003-2460-3036
Pellman, David https://orcid.org/0000-0001-5306-8031
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA213404, K22CA216319)
National Science Foundation (DGE1144152)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F32 DK118822)
Assisi Foundation of Memphis
St. Jude Children’s Research Hospital
American Lebanese Syrian Associated Charities
- License Information
-
More Information
Article History
Received: 2 July 2020
Accepted: 8 March 2021
First Online: 12 April 2021
Competing interests
: M.J.W. is a consultant for Rubius Inc., Cellarity Inc., Beam Therapeutics and Esperion; none of the consulting work is relevant to the current project. C.-Z.Z. is a scientific adviser for Pillar BioSciences. D.P. is a member of the Volastra Therapeutics scientific advisory board. All other authors declare no competing interests.
